ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 521

Differences in Genome-Wide DNA Methylation Profiles Across Multiple Cell and Tissue Types in Sjögren’s Syndrome (SS)

Lindsey A. Criswell1, Diana Quach2, Hong L. Quach2, Emon Elboudwarej2 and Lisa F. Barcellos2, 1Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, 2Epidemiology, University of California, Berkeley, Berkeley, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: B cells, epigenetics and monocytes, Sjogren's syndrome, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjögren's Syndrome - Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Increasing evidence supports a role for epigenetic factors, including DNA methylation status, in autoimmune disease risk and severity. Our goal is to characterize DNA methylation profiles in SS, including multiple cell and tissue types relevant to disease.

Methods: We generated genome-wide DNA methylation profiles using Illumina HumanMethylation450 bead chips in minor salivary gland biopsy tissue, parotid saliva, PBMCs, and the following cell subpopulations: CD14+ monocytes, CD19+ B cells, and CD4+ T cells in a subset of participants from the Sjögren’s International Collaborative Clinical Alliance (SICCA) repository (http:/sicca.ucsf.edu/). All subjects were Caucasian females. SS cases (n=5) had severe disease, meeting all 3 of the ACR classification criteria for SS (Arth Care & Res 2012; 64:475), including focal lymphocytic sialadenitis on minor salivary gland biopsy, keratoconjunctiva sicca based on ocular staining pattern (ocular staining score ≥ 3), and presence of SSA and/or SSB autoantibodies. A single control individual with no evidence of SS based on the aforementioned and other objective tests was also studied. Sorting of freshly collected blood samples was performed using MACS® technology. Labial salivary gland biopsy tissue, parotid saliva and PBMCs were collected at entry to the SICCA repository, and a second blood sample was collected from each subject for isolation of the aforementioned cell subpopulations an average of 4.4 years following the baseline visit. Genome-wide DNA methylation profiles (450k sites) were compared across the 7 cell and tissue types within the 6 study subjects to characterize cell and tissue differences in DNA methylation status.  

Results: DNA yields for all cell and tissue types were high, with the exception of parotid saliva, which yielded between 0.75 – 1.07 µg DNA but was still sufficient for whole genome methylation profiling. Assessments of purity for sorted cell subpopulations ranged from a mean of 59% (for CD4+ T cells) to 80% (for CD14+ monocytes).  Within-individual comparisons of tissue-specific genome wide DNA methylation profiles revealed striking differences, with r2ranging from 0.105 (for saliva vs. B cells) to 0.998 (baseline vs. followup PBMCs).   

Conclusion: These preliminary results emphasize the cell and tissue specificity of DNA methylation status, which is an important epigenetic process with potential to influence patterns of gene expression in health and disease. Additional work, including detailed analysis of site-specific DNA methylation differences in larger samples of SS case and control individuals, followed by studies of gene expression for regions associated with disease risk or severity will be required to fully define the role of DNA methylation in SS.


Disclosure:

L. A. Criswell,
None;

D. Quach,
None;

H. L. Quach,
None;

E. Elboudwarej,
None;

L. F. Barcellos,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differences-in-genome-wide-dna-methylation-profiles-across-multiple-cell-and-tissue-types-in-sjogrens-syndrome-ss/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology